Vivos Therapeutics (VVOS)
(Real Time Quote from BATS)
$2.61 USD
-0.04 (-1.51%)
Updated Apr 24, 2024 01:40 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VVOS 2.61 -0.04(-1.51%)
Will VVOS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VVOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VVOS
Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)
Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher
VVOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
Other News for VVOS
Why Is Laser Photonics (LASE) Stock Up 130% Today?
Medicare to reimburse for Vivos CARE sleep apnea devices
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
Vivos gets approvals to enable Medicare reimbursement for CARE oral devices